KILR Effector Cells

Driving Robust and Reproducible ADCC and T Cell Redirection
 

PBMC effector cells have inherent donor variability, reducing their consistency and reproducibility in lot release assays. Antibody- Dependent Cell Cytotoxicity (ADCC) assays that measure cell death often have low signal to background ratios and suffer from this donor variability of the PBMCs. The KILR CD16 Effector Cells are single donor-derived human primary cells to measure target cell death using ADCC and bi-specific antibody-mediated T Cell Redirection (TCR) assays for screening, characterization, and QC lot release of antibody drugs. These effector cells ensure assay reproducibility with higher signal to background ratios, without worrying about donor variability.


 
View Flyer Scientific Poster Watch Webinar


KILR CD16 Effector Cells Advantages

  • Eliminate Donor Variability - Primary effector cells from a single donor
  • Fit for Long-Term QC Testing - High lot-to-lot reproducibility with frozen ready-to-use cells
  • Measure Target Cell Death - Biologically relevant measure of ADCC and TCR
 

KILR Cytotoxicity Assays Have Broad Applications in:

    
 

Higher Signal:Background Ratios Deliver Better Accuracy and Linear Range



The KILR CD16 Effector Cells provide a significantly larger assay window in comparison to PBMCs. A killing- resistant HER2+ cell line, SKOV-3 was opsonized with trastuzumab and incubated with the effector cells for 3 hours. A 16-fold larger assay window was observed relative to PBMCs in this SKOV-3 cell model. These effector cells have much lower background with higher S:B ratios, resulting in better analysis of the antibody activity.
 

QC-Friendly, Ready-to-Use Effector Cells



KILR CD16 Effector Cells were thawed, then maintained in AssayComplete™ Cell Culture Kit 117 for the  indicated number of days prior to use in ADCC assay with KILR Raji cells. These effector cells can be used in the ADCC assay after a resting period of 24 hours and show no reduction in their killing capacity even when
used on day 3 post-thaw. This easy-to-use format with robust performance allows for an easy implementation into QC as a lot release assay.
 

High Lot-to-Lot Reproducibility Ensures Long-Term Support for QC Testing



Four different production batches of KILR CD16 Effector Cells were tested for ADCC activity in a single  experiment in the anti-human CD20 model. No significant variation in the killing capacity of the cells was observed. This excellent lot-to-lot reproducibility demonstrates the ability of these cells to deliver consistent and reproducible performance throughout the life of the drug from development to post-market.
 

Ordering Information

Product Catalog Number
KILR CD16 Effector Cells, 1 Vial 97-0007-01
KILR CD16 Effector Cells, 5 Vials 97-0007-05